Dr. Krampitz on Therapeutic Targets in pNETs

Geoffrey Krampitz, MD
Published: Thursday, Jan 21, 2016



Geoffrey Krampitz, MD, Department of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, identifies tumorigenic cells and therapeutic targets in patients with pancreatic neuroendocrine tumors (pNETs).

Anti-CD47 agents and their safety profiles are currently being investigated in a phase I clinical trial, Krampitz explains. Community oncologists, he adds, should be aware of this class of drugs eventually coming down the pipeline.

Regarding safety, preclinical models reported low-grade anemia associated with anti-CD47 agents. However, this has not yet been observed in the phase I data, Krampitz adds.

SELECTED
LANGUAGE


Geoffrey Krampitz, MD, Department of Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, identifies tumorigenic cells and therapeutic targets in patients with pancreatic neuroendocrine tumors (pNETs).

Anti-CD47 agents and their safety profiles are currently being investigated in a phase I clinical trial, Krampitz explains. Community oncologists, he adds, should be aware of this class of drugs eventually coming down the pipeline.

Regarding safety, preclinical models reported low-grade anemia associated with anti-CD47 agents. However, this has not yet been observed in the phase I data, Krampitz adds.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Oncology Consultations®: Discussing the Nurse's Role in Treating and Managing Advanced Pancreatic AdenocarcinomaSep 28, 20191.5
Publication Bottom Border
Border Publication
x